2021/01/06 16:30:06 | |
---|---|
Price | |
158.6075 USD | |
Difference | 2.29% (3.55) |
ISIN | US0153511094 |
Symbol | ALXN |
Exchange | London Stock Exchange |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 28,727 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 158.6075 USD |
High | 158.6075 USD |
Low | 158.6075 USD |
Close (prev. day) | 155.0604 USD |
VWAP | 158.60754 USD |
Volume (pcs) | 285 |
Trading volume | 45,203.15 |
Number of trades | 1 |
Last size | 285 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2021/01/18 |
![]() |
Aktienempfehlungen Österreich |
![]() |
2021/01/18 |
![]() |
Aktienempfehlungen Österreich |
![]() |
2021/01/11 |
![]() |
Aktienempfehlungen Österreich |
![]() |
2021/01/08 |
![]() |
Equity Weekly |
![]() |
2021/01/08 |
![]() |
Global Equity Ratings |
![]() |
2021/01/06 16:30:06 | |
---|---|
Price | |
158.6075 USD | |
Difference | 2.29% (3.55) |
ISIN | US0153511094 |
Symbol | ALXN |
Exchange | London Stock Exchange |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 28,727 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 158.6075 USD |
High | 158.6075 USD |
Low | 158.6075 USD |
Close (prev. day) | 155.0604 USD |
VWAP | 158.60754 USD |
Volume (pcs) | 285 |
Trading volume | 45,203.15 |
Number of trades | 1 |
Last size | 285 |
6M | 1Y | 3Y | |
Perf (%) | - | - | - |
Perf (abs.) | - | - | - |
Beta | 0.89 | 0.70 | 0.90 |
Volatility | 21.80 | 14.67 | 33.65 |
Ø price 5 days | Ø volume 5 days (pcs.) | - USD (34) |
Ø price 30 days | Ø volume 30 days (pcs.) | 29.0243 USD (7,466) |
Ø price 100 days | Ø volume 100 days (pcs.) | 34.8105 USD (2,792) |
Ø price 250 days | Ø volume 250 days (pcs.) | 24.2128 USD (1,570) |
YTD High | date | 158.6075 USD (2021/01/06) |
YTD Low | date | 158.6075 USD (2021/01/06) |
52 Weeks High | date | 163.9700 USD (2020/12/14) |
52 Weeks Low | date | 79.9366 USD (2020/03/13) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Xetra | 2021/01/22 | 17:35 | 130.94 EUR | 0.01 | 3 |
Vienna Stock Exchange | 2021/01/25 | 09:05 | 132.14 EUR | 0.00 | 1 |
Tradegate | 2021/01/22 | 22:26 | 131.24 EUR | 0.00 | 2 |
Stuttgart | 2021/01/25 | 08:14 | 131.90 EUR | 0.00 | 1 |
Nasdaq | 2021/01/22 | 22:00 | 159.73 USD | 445.35 | 26,861 |
Munich | 2021/01/25 | 08:03 | 131.56 EUR | 0.00 | 1 |
London Stock Exchange | 2021/01/06 | 16:30 | 158.6075 USD | 0.05 | 1 |
Frankfurt | 2021/01/25 | 08:14 | 131.56 EUR | 0.00 | 1 |
Duesseldorf | 2021/01/25 | 09:00 | 131.56 EUR | 0.00 | 3 |
Berlin | 2021/01/25 | 08:08 | 131.72 EUR | 0.00 | 1 |
ALEXION PHARMACEUTICALS INC. |
Chris Stevo |
Seaport Boulevard 121 02210 Boston Massachusetts |
Telefon: +1-475-230-2596 |
Fax: +1-203-271-8198 |
E-mail: IR@Alexion.com |
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders. As the global leader in complement inhibition, Alexion is strengthening and broadening its portfolio of complement inhibitors, including evaluating potential indications for eculizumab in additional severe and ultra-rare disorders. Alexion's metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders, Strensiq® (asfotase alfa) to treat patients with hypophosphatasia (HPP) and Kanuma® (sebelipase alfa) to treat patients with lysosomal acid lipase deficiency (LAL-D). In addition, Alexion is advancing the most robust rare disease pipeline in the biotech industry with highly innovative product candidates in multiple therapeutic areas. |
David R. Brennan | Chairman of Board of Directors |
Paul A. Friedman | Member of Board of Directors |
Ludwig N. Hantson | Member of Board of Directors |
Judith Reinsdorf | Member of Board of Directors |
John T. Mollen | Member of Board of Directors |
Francois Nader | Member of Board of Directors |
Deborah Dunsire | Member of Board of Directors |
Christopher J. Coughlin | Member of Board of Directors |
Felix J. Baker | Member of Board of Directors |
Andreas Rummelt | Member of Board of Directors |
Ludwig N. Hantson | Chairman of Managing Board |
Uzair Qadeer | Member of Executive Committee |
Tanisha Carino | Member of Executive Committee |
Rana Strellis | Member of Executive Committee |
Morgan Sanford | Member of Executive Committee |
John Orloff | Member of Executive Committee |
Indrani Franchini | Member of Executive Committee |
Ellen Chiniara | Member of Executive Committee |
Brian Goff | Member of Executive Committee |
Aradhana Sarin | Member of Executive Committee |
Any information, material and services regarding financial instruments and securities provided by Erste Group Bank AG or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites”) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions (the “Interested Party“).
The publication and distribution of information as well as offering and selling of products and services described on the Websites is prohibited by law in some jurisdictions. For this reason, persons in countries in which the publication as well as the offering and selling of products and services described on the Websites are not permitted by law, must not enter the Websites and/or acquire the products displayed on the Websites.
Neither Erste Group nor any third party shall offer access to the Websites or offer the products to especially, but not limited to citizen/residents of the United States and “U.S. person” (as defined in Regulation S under the US Securities Act 1933 as amended). For this reason, the distribution or redistribution of the information, materials and products into United States or into any other jurisdiction where it is not permitted under the applicable law, as well as to the citizens/residents of these countries shall be prohibited. The securities displayed on the Websites have not been and will not be registered under the US Securities Act of 1933 and trading in the securities has not been approved for purposes of the US Commodities Exchange Act of 1936. For this reason the securities may, inter alia, not be offered, sold or delivered within the United States or, for the account and benefit of U.S. persons.
The Interested Party is solely responsible to examine, whether he may enter the Websites under the law applicable to it. Erste Group shall not be responsible for the distribution of content of any of the Websites to individuals or entities which provide false information about their right to enter the Websites. For this reason Erste Group shall not be liable for any legal claims or damages which may result from the unauthorized entering or reading of the Websites.
By agreeing to this hereto, the Interested Party confirms that
(i) It has read, understood and accepted this Information and the Disclaimer;
(ii) It informed itself about any possible legal restriction and warrants that it is not restricted or prohibited to enter the Websites according to any law applicable; and
(iii) It does not make available the contents of the Websites to any person who is not qualified by law to enter the Websites.